Brian Lee, Ph.D., CEO Oct. 13 | 3:45pm | BlueRock Therapeutics Ballroom Camarillo, CA (Private) In-person Presentation PBS Biotech develops and manufactures the most advanced single-use bioreactors for the rapidly growing cell and gene therapy market. Vertical-Wheel mixing technology uniquely provides the beneficial hydrodynamic conditions for optimal production of various...

Ivan Dimov, Ph.D., CEO and Co-Founder  Oct. 12 | 11:15am | BlueRock Therapeutics Ballroom Menlo Park, CA (Private) In-person Presentation Established in 2016, Orca Bio is a clinical-stage biotechnology company developing a pipeline of high-precision allogeneic cell therapy products. Our products are designed to safely and effectively replace a patient’s...

Yan Zhang, Ph.D., CEO Oct. 13 | 4:30pm | AVROBIO Ballroom San Francisco, CA (Private) In-person Presentation Mission Bio unlocks the ground truth of cancer through response, relapse, and remission with its Tapestri Platform, powered by single-cell multi-omics. As the first and only to analyze genotype and phenotype simultaneously in...

Sarah Meeks, Ph.D., Vice President of Business Development Oct. 13 | 5:00pm | AVROBIO Ballroom Gaithersburg, MD (NASDAQ: MXCT) In-person Presentation MaxCyte is a clinical-stage global cell-based therapies and life sciences company applying its proprietary cell engineering platform to deliver the advances of cell-based medicine to patients with high unmet...

Sean Ainsworth, Chairman and CEO Oct. 13 | 3:15pm | BlueRock Therapeutics Ballroom Seattle, WA (Private) In-person Presentation Immusoft is developing a cutting-edge approach to sustained delivery of protein therapeutics using a patient’s own cells. The approach is called Immune System Programming (ISP). ISP entails collecting a type of the...

Dale Sander, Chief Corporate Development Officer, Chief Financial Officer and Treasurer Oct. 14 | 9:30am | BlueRock Therapeutics Ballroom Durham, NC (Private) In-person Presentation Humacyte is a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at a commercial scale to improve the lives of patients and transform the...

Kunwoo Lee, Ph.D., CEO Oct. 12 | 5:45pm | BlueRock Therapeutics Ballroom San Francisco, CA (Private) In-person Presentation GenEdit is a genetic medicine company revolutionizing a new, targeted gene therapy approach to more safely and efficiently deliver medicine. We leverage our systematic screening, iterative design, and delivery platform to advance...

Timothy Miller, Ph.D., President, CEO, and Co-Founder Oct. 12 | 5:00pm | BlueRock Therapeutics Ballroom Columbus, OH (Private) In-person Presentation Forge Biologics is a hybrid gene therapy contract manufacturing and therapeutics development company. Forge’s mission is to enable access to life changing gene therapies and help bring them from idea...

Rachelle Jacques, CEO Oct. 13 | 2:15pm | BlueRock Therapeutics Ballroom Cambridge, MA (Private) In-person Presentation Enzyvant Therapeutics is a biotechnology company dedicated to developing novel, transformative regenerative therapies for people with devastating rare diseases. Enzyvant’s lead asset is the investigational tissue-based regenerative therapy, RVT-802, for congenital athymia, an ultra-rare...

Naina Bashin, Ph.D., Chief Business Officer Oct. 12 | 11:00am | BlueRock Therapeutics Ballroom Boston, MA (Private) In-person Presentation Ensoma is expanding the reach of the curative power of precision genomic medicine by pioneering an off-the-shelf and portable in vivo approach using its Engenious™ vectors. Ensoma’s vectors are designed to...

By using this website you agree to accept our Privacy Policy and Terms & Conditions